Santhera Pharmaceuticals Holding, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a CHF30.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors related to Santhera’s leadership and commercial trajectory. He emphasizes the appointment of Orlando Oliveira as CEO, noting Oliveira’s extensive global biopharma background, success in specialty and rare diseases, and demonstrated ability to scale organizations and execute value-creating transactions across multiple regions.
Selvaraju also highlights the solid platform established under outgoing CEO Dario Eklund, who repositioned Santhera into a focused commercial rare-disease company built around AGAMREE. With recent approvals of AGAMREE in the U.S., Europe, and the UK and launches underway, alongside strengthened finances and global partnerships, Selvaraju sees a favorable setup for continued revenue growth, supporting his reiterated Buy rating and unchanged $30 price target.